Skip to content

OWP Pharmaceuticals Announces IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder

Share this press release:

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved. Social Media Policy | Terms of Use

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved.
Social Media Policy | Terms of Use

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved. Social Media Policy | Terms of Use